Advice

following a full submission:

upadacitinib (Rinvoq®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.

SMC restriction: in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs and in patients with severe disease inadequately controlled by a TNF antagonist in whom rituximab is not appropriate.

Upadacitinib (with or without methotrexate) compared with placebo, significantly improved signs and symptoms of RA in patients with an inadequate response to conventional DMARDs and in patients with an inadequate response to biological DMARDs. Upadacitinib was non-inferior to a biologic DMARD in patients who had an inadequate response to methotrexate.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Medicine details

Medicine name:
upadacitinib (Rinvoq)
SMC ID:
SMC2315
Indication:

For treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.

Pharmaceutical company
AbbVie Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Status
Restricted
Date advice published
08 February 2021